Genomic analysis revealed that TTN mutations induced CD8+ and CD4+ T cell infiltration (47); TP53 mutations affected cell cycle and DNA repair and remodeled the immune microenvironment (48); MUC16 mutations increased neoantigen production but may inhibit NK cell killing (49, 50); and ARID1A mutations regulated the tumor inflammatory microenvironment and may enhance immunotherapy sensitivity (51). The gene discussed is ARID1A; the disease is neoplasm.